Medical Research Sample Clauses

Medical Research. The Parties agree that:

Medical Research. The Parties agree that: (a) JHINV will contribute an amount of $500,000 per annum for a period of 10 years (starting on the Commencement Date and payable on or by each anniversary thereof) for the purposes of conducting or funding the conduct of medical research into the diagnosis and treatment of Asbestos diseases on the basis that: (i) JHINV administers its own medical research grants scheme with the assistance of relevant experts to review and make recommendations concerning the expressions of interest and research proposals; and (ii) any Funds not used in any particular year can be carried over and added to the next year’s funding amount; (b) JHINV will, within 6 months of the Commencement Date, establish a trust for the purposes of conducting or funding the conduct of medical research into the diagnosis and treatment of Asbestos diseases and ensure that all funds paid to that trust are maintained in one or more bank accounts to be used only for the purposes of the trust; (c) the trustee of the medical research trust will at all times be a member of the JHINV Group determined by JHINV in its discretion; (d) the awarding of medical research grants from the proceeds of the trust shall be a matter for the trustee to determine in accordance with the purposes of the trust; and (e) on and from the time the final payment required under this clause 20.1 is made, or if for any reason the trust determines earlier than on the tenth anniversary of the Commencement Date, JHINV may at its election, by Notice to the NSW Government determine the medical research trust and in any such case any resulting surplus funds and any amounts not then due and payable under clause 20.1(a) shall be paid to one or more medical research institutions selected by agreement between JHINV and the NSW Government which are of good repute and which conduct medical research into the diagnosis and treatment of Asbestos diseases (and on such terms as JHINV may consider reasonable to ensure that such funds are only expended on such medical research into Asbestos diseases).

Medical Research. COUNCIL The MRC hereby excludes from its obligation to grant Access Rights to Pre-existing Know-how: (i) All MRC Pre-existing Know-how other than that generated by the MRC research group lead by ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, MRC Human Immunology Unit; and (ii) All MBP-TCR transgenic mice and MHC class I and II transgenic mice held by the MRC. The MRC informs all Contractors, in accordance with Article II.36 of the Contract, that it will be unable to grant Access Rights to certain PEKH held by the MRC, which is personally owned by ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇. Any request for Access Rights to such PEKH should be addressed directly to ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇.All MBP-TCR transgenic mice and MHC class I and II transgenic mice are excluded from the other partner’s access 5 Medical University of Vienna All prePre-existing knowKnow-how deriving from Research Groups and Departments of the Medical University of Vienna other than the research group directed by Prof. Dr. ▇▇▇▇ ▇▇▇▇▇▇▇▇ at the Center for Brain Research, Division of Neuroimmunology, Medical University of Vienna, Austria is excluded from the other partners’ accessAccess Rights.

Medical Research. What’s it worth? Estimating the economic benefits from medical research in the UK. London. ▇▇▇▇▇▇▇, ▇. ▇. & ▇. ▇▇▇ ▇▇▇▇▇. (2008). ‘Re-Thinking New Knowledge Production: A Literature Review and a Research Agenda’. In: Research Policy 37, no. 4, pp. 740–60. ▇▇▇▇▇▇▇▇, E., ▇. ▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇ & P. ▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇. (2012). The Societal Footprint of Large Research Facilities (working paper 1206). Den ▇▇▇▇: ▇▇▇▇▇▇▇▇ Instituut. IPCC, 2012: Summary for Policymakers. In: Managing the Risks of Extreme Events and Disasters to Advance Climate Change Adaptation (eds.: ▇▇▇▇▇, ▇.▇., ▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇, D.J. ▇▇▇▇▇▇, ▇.▇. ▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇, ▇. ▇.▇. ▇▇▇▇▇▇▇▇, ▇. Kreimer & ▇. ▇▇▇▇▇▇▇▇▇. (2008). Scientists who engage with society perform better academically. In: Science and Public Policy 35, no. 7, pp. 527-541. ▇▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇ & ▇. ▇▇▇.(2009). ‘Key Stakeholders’ Experiences and Views of the NHS End of Life Care Programme: Findings from a National Evaluation’. In: Palliative Medicine 23, no.4, pp. 283-294. ▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇ & ▇. ▇▇▇. (2013). ‘Applying the Criteria Indicators and Metrics Evaluation Method on ICT Research: The HUMBOLDT Project’. In: Research Evaluation 22, no. 2, pp. 30-40. ▇▇▇▇▇▇▇▇, G. B. ▇▇▇▇▇▇▇ & ▇. ▇▇▇▇▇. (1996). ‘Technology Transfer and Absorption: An “R&D Value Mapping” Approach to Evaluation’. In: Research Policy 25, pp. 967-995. ▇▇▇▇▇▇▇▇, ▇. & ▇.▇. ▇▇▇▇▇▇ (1997). ‘Using Technology Absorption as an Evaluation Criterion: Case Studies from a State Research and Development Program’. In: Policy Studies Journal 25, no. 3, pp. 436-450. Krücken, ▇. ▇. ▇▇▇▇▇ & ▇. ▇▇▇▇▇▇. (2009). ‘Linkages to the Civil Society as “leisure time activities”? Experiences at a German university’. In: Science and Public Policy 36, no. 2, pp. 139-144. ▇▇▇, ▇. (2011). ‘What Motivates Academic Scientists to Engage in Research Commercialization: “Gold”, ‘ribbon” or “puzzle”?’. In: Research Policy 40, no. 10, pp. 1354-1368. ▇▇▇▇, ▇. (2010). ‘Let’s make Science Metrics more Scientific’. Nature 464, pp. 488-489. Library House. (2006). The Impact of the University of Cambridge on the UK Economy and ▇▇▇▇▇▇▇▇, ▇. (2011). ‘Co-producing European Climate Science and Policy: A Cautionary Note on the Making of Useful Knowledge’. Science and Public Policy 38, no. 3, pp. 225-236. ▇▇▇▇, ▇.▇., G.-▇. ▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇, ▇. ▇▇▇▇▇▇, and ▇.▇. ▇▇▇▇▇▇▇. A Special Report of Working Groups I and II of the Intergovernmental Panel on Climate Change. Cambridge, UK, an...

Medical Research. Subject to clause 20.3, the Parties agree that: